“The first quarter of 2025 has been highly productive and sets a strong foundation for the year ahead. We are well positioned to advance Olvi-Vec across multiple high-need cancer indications, with encouraging regulatory feedback from the FDA on our OnPrime Phase 3 registrational trial in resistant/refractory ovarian cancer, promising early lung cancer clinical data from our ongoing Phase 1b/2 study, and increasing patient enrollment in our U.S. Phase 2 lung cancer trial” said Thomas Zindrick, President, CEO and Chairman of Genelux (GNLX). “We are energized by our momentum and look forward to advancing our strategic initiatives through key upcoming value inflection points this year and into 2026.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNLX:
- Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements
- Genelux reports FY24 EPS (95c), consensus (88c)
- Promising Clinical Trial Results and Strong Financial Position Justify Buy Rating for Genelux Corp.
- Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec
- Genelux announces alignment with FDA of approval pathway for Olvi-Vec